ES8705875A1 - Procedimiento para preparar dialcoxipiridinas - Google Patents

Procedimiento para preparar dialcoxipiridinas

Info

Publication number
ES8705875A1
ES8705875A1 ES544204A ES544204A ES8705875A1 ES 8705875 A1 ES8705875 A1 ES 8705875A1 ES 544204 A ES544204 A ES 544204A ES 544204 A ES544204 A ES 544204A ES 8705875 A1 ES8705875 A1 ES 8705875A1
Authority
ES
Spain
Prior art keywords
alkoxy
fluorine
alkyl
medicaments containing
dialkoxyridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES544204A
Other languages
English (en)
Spanish (es)
Other versions
ES544204A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25691679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8705875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of ES8705875A1 publication Critical patent/ES8705875A1/es
Publication of ES544204A0 publication Critical patent/ES544204A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES544204A 1984-06-16 1985-06-14 Procedimiento para preparar dialcoxipiridinas Expired ES8705875A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH289984 1984-06-16
CH290184 1984-06-16

Publications (2)

Publication Number Publication Date
ES8705875A1 true ES8705875A1 (es) 1987-06-01
ES544204A0 ES544204A0 (es) 1987-06-01

Family

ID=25691679

Family Applications (1)

Application Number Title Priority Date Filing Date
ES544204A Expired ES8705875A1 (es) 1984-06-16 1985-06-14 Procedimiento para preparar dialcoxipiridinas

Country Status (22)

Country Link
US (1) US4758579A (enExample)
EP (1) EP0166287B1 (enExample)
AU (1) AU578703B2 (enExample)
BG (1) BG61322B2 (enExample)
CA (1) CA1254215A (enExample)
CY (1) CY1670A (enExample)
CZ (1) CZ281242B6 (enExample)
DE (2) DE19475025I2 (enExample)
DK (1) DK170440B1 (enExample)
ES (1) ES8705875A1 (enExample)
GR (1) GR851399B (enExample)
HK (1) HK86894A (enExample)
IE (1) IE58117B1 (enExample)
IL (1) IL75400A (enExample)
LU (1) LU88700I2 (enExample)
MY (1) MY103021A (enExample)
NL (1) NL950030I2 (enExample)
NZ (1) NZ212415A (enExample)
PH (2) PH21850A (enExample)
PT (1) PT80641B (enExample)
SG (1) SG80192G (enExample)
SK (1) SK278401B6 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185459A1 (es) * 2000-10-02 2003-04-16 Dinamite Dipharma Spa Procedimiento para la obtencion de pantoprazol y compuestos intermedios para el mismo.

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW4585A1 (en) * 1984-04-19 1985-11-20 Hoffmann La Roche Imidazole derivatives
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ220022A (en) * 1986-04-22 1990-04-26 Byk Gulden Lomberg Chem Fab 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3621215A1 (de) * 1986-06-25 1988-01-07 Bayer Ag Fluorhaltige o-phenylendiamine und o-aminophenole
HU204828B (en) * 1987-07-16 1992-02-28 Byk Gulden Lomberg Chem Fab Process for producing new diazole derivatives and pharmaceutical compositions comprising such compounds
AU2817989A (en) * 1987-12-11 1989-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzimidazole derivatives
DE4018642C2 (de) * 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
FR2665158B1 (fr) * 1990-07-30 1993-12-24 Air Liquide Clathrates de peroxyacides.
CA2053527C (en) * 1990-10-17 2002-03-12 Takashi Sohda Pyridine derivatives, their production and use
KR950702416A (ko) * 1992-07-08 1995-07-29 제임스 클리프튼 보올딩 돼지에서 위궤양을 완화시키기 위한 벤즈이미다졸(Benzimidazoles for alloviating stomach ulcers in swine)
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
AU4504000A (en) * 1993-04-27 2000-09-07 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
CA2161130A1 (en) * 1993-04-27 1994-11-10 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
TW280770B (enExample) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
CN1045773C (zh) * 1994-06-23 1999-10-20 沈阳药科大学 吡啶衍生物的制备方法
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
PT854718E (pt) * 1995-09-21 2004-08-31 Pharma Pass Ii Llc Composicao farmaceutica contendo um benzimidazole acido-labil e processo para a sua preparacao
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6380222B2 (en) * 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
AU6551198A (en) * 1997-05-30 1998-12-30 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
DE19745692A1 (de) * 1997-07-24 1999-01-28 Bayer Ag Verfahren zur Herstellung von 2-Chlor-benzimidazol-Derivaten
AU9067198A (en) 1997-07-25 1999-02-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
WO1999059544A2 (en) 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
WO2000000474A1 (en) * 1998-06-26 2000-01-06 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
EP1105387B1 (en) * 1998-08-10 2003-01-29 Winston Pharmateuticals LLC Prodrugs of proton pump inhibitors
SI1105105T1 (sl) 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
JP4980527B2 (ja) 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US7988999B2 (en) 2000-12-07 2011-08-02 Nycomed Gmbh Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
JP5009482B2 (ja) 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
EP1379167A1 (en) * 2001-04-06 2004-01-14 Medic4all Inc. A physiological monitoring system for a computational device of a human subject
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
KR20040025677A (ko) * 2001-09-18 2004-03-24 제리아 신야쿠 고교 가부시키 가이샤 벤즈이미다졸 유도체
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
CN100577164C (zh) 2002-04-09 2010-01-06 弗拉梅技术公司 可改进释放阿莫西林的微囊含水混悬液形式的口服药物制剂
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
MXPA05005762A (es) 2002-12-06 2005-08-16 Altana Pharma Ag Procedimiento para preparar compuestos activos opticamente puros.
ES2383679T3 (es) 2002-12-06 2012-06-25 Nycomed Gmbh Procedimiento para la preparación de (S)-pantoprazol
EP1572680A2 (en) 2002-12-19 2005-09-14 Eva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, known pantoprazole sodium hydrates, processes for their preparation.
RU2345075C2 (ru) * 2003-01-15 2009-01-27 Сипла Лимитед Способ получения фармацевтических средств и соединения, полученные данным способом
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
WO2004080487A1 (ja) * 2003-03-13 2004-09-23 Eisai Co. Ltd. 歯ぎしりの予防剤または治療剤
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2004101533A1 (en) * 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
US7683177B2 (en) 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AU2004264401A1 (en) * 2003-07-15 2005-02-24 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
EP1711179A2 (en) * 2004-01-28 2006-10-18 Altana Pharma AG Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
WO2005082337A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
MXPA06009991A (es) * 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
AR048631A1 (es) * 2004-04-28 2006-05-10 Altana Pharma Ag Derivados de dialcoxi-imidazopiridinas, composiciones farmaceuticas que los contienen y usos,
DK1746980T3 (da) * 2004-05-07 2012-01-30 Nycomed Gmbh Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
TW200613301A (en) * 2004-06-15 2006-05-01 Altana Pharma Ag Novel amino-halogen-imidazopyridines
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
KR20070109985A (ko) 2004-11-22 2007-11-15 아나디스 리미티드 생물활성 조성물
AU2005315390B2 (en) * 2004-12-16 2011-10-27 Cipla Limited Process for the preparation of pantoprazole sodium
WO2007036771A2 (en) * 2005-05-06 2007-04-05 Medichem, S.A. Pantoprazole free acid form iii
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
EP1747776A1 (en) 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
WO2007026188A1 (en) * 2005-09-01 2007-03-08 Wockhardt Limited Process for the manufacture of antiulceratives
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
WO2007086077A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited A novel one pot process for preparation of pantoprazole sodium sesquihydrate
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
BRPI0711048A2 (pt) * 2006-05-09 2011-08-23 Astrazeneca Ab formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007146341A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of pantoprazole magnesium salt
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
SI2124884T1 (sl) 2006-12-22 2019-09-30 Ironwood Pharmaceuticals, Inc. Pripravki, ki obsegajo sekvestrante žolčnih kislin, za zdravljenje motenj požiralnika
US20100145057A1 (en) * 2007-03-15 2010-06-10 Sun Pharma Advanced Research Company Ltd. Novel prodrugs
US20100210847A1 (en) * 2007-07-17 2010-08-19 Ranbaxy Laboratories Limited Process for the preparation of pantoprazole sodium and pantoprazole sodium sesquihydrate
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CA2740095A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
CN105338958A (zh) 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
WO2014160405A1 (en) * 2013-03-13 2014-10-02 University Of Iowa Research Foundation Compounds, compositions comprising same, and methods related thereto
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
CN110487918B (zh) * 2018-05-14 2022-02-08 中国医学科学院药物研究所 泮托拉唑钠及其起始原料中基因毒性杂质的分析方法
MX2022002949A (es) 2019-09-24 2022-04-06 Prolacta Bioscience Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.
EP4204422A1 (en) 2020-08-26 2023-07-05 Syngenta Crop Protection AG Process for the preparation of 2,2-difluoro-1,3-benzodioxole derivatives with sulfur containing substituents
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234058A (enExample) * 1968-10-21 1971-06-03
IL57005A (en) * 1978-04-11 1983-11-30 Smith Kline French Lab Process for the preparation of 2-amino pyrimid-4-one derivatives and novel 2-nitroaminopyrimid-4-ones as intermediates therefor
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
IL71664A (en) * 1983-05-03 1987-11-30 Byk Gulden Lomberg Chem Fab Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
HU191756B (en) * 1983-05-03 1987-04-28 Byk Gulden Lomberg Chem Fab Process for preparing new fluoro-alkoxy-benzimidazole derivatives
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185459A1 (es) * 2000-10-02 2003-04-16 Dinamite Dipharma Spa Procedimiento para la obtencion de pantoprazol y compuestos intermedios para el mismo.

Also Published As

Publication number Publication date
SK278401B6 (en) 1997-04-09
HK86894A (en) 1994-09-02
NL950030I2 (nl) 1996-12-02
DK170440B1 (da) 1995-09-04
DK268285A (da) 1985-12-17
EP0166287A1 (de) 1986-01-02
AU4364085A (en) 1985-12-19
PT80641B (de) 1987-04-28
MY103021A (en) 1993-04-30
NZ212415A (en) 1989-03-29
BG61322B2 (bg) 1997-05-30
PH23729A (en) 1989-11-03
EP0166287B1 (de) 1989-08-23
IE58117B1 (en) 1993-07-14
PH21850A (en) 1988-03-25
US4758579A (en) 1988-07-19
IL75400A (en) 1988-10-31
AU578703B2 (en) 1988-11-03
IE851478L (en) 1985-12-16
CY1670A (en) 1993-10-10
NL950030I1 (enExample) 1996-02-01
DE3572488D1 (en) 1989-09-28
CZ281242B6 (cs) 1996-07-17
CA1254215A (en) 1989-05-16
DK268285D0 (da) 1985-06-13
GR851399B (enExample) 1985-11-25
LU88700I2 (fr) 1996-04-29
IL75400A0 (en) 1985-10-31
PT80641A (de) 1985-07-01
ES544204A0 (es) 1987-06-01
DE19475025I2 (de) 2009-01-02
SG80192G (en) 1992-12-04
CS396491A3 (en) 1992-09-16

Similar Documents

Publication Publication Date Title
ES8705875A1 (es) Procedimiento para preparar dialcoxipiridinas
IL71664A (en) Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
ES8400737A1 (es) "un procedimiento para preparar derivados de nicotinamida".
PH15864A (en) 2-(2-alkoxy-methyl)-2-hydroxy-6-7 benzomorphans and salts thereof
ES8405008A1 (es) Un procedimiento para la preparacion de imidazodiacepinas.
ES8506652A1 (es) Un metodo de preparar dihidrobenzopirrolbenzodiazepinas
SE8102220L (sv) Anvendning av substituerade derivat av 4-fenyl-4-oxo-2-butensyra sasom lekemedel
HUT43943A (en) Herbicide compositions comprising urea derivatives as active substance and process for preparing such compounds
DE3261844D1 (en) Pyridine carbinols, process for their preparation and fungicides containing them
ES8401068A1 (es) Procedimiento para la preparacion de derivados de corinanteina, asi como de sus sales de adicion acida fisiologicamente inocuas.
DE3474298D1 (en) Derivatives of 4-phenyl-4-oxo-buten-2-oic acid, their preparation, medicaments and compositions containing them
ES480827A1 (es) Procedimiento para la preparacion de acidos fenilaminotiofe-noaceticos.
AU3878585A (en) Isoxazole derivatives
ES477878A1 (es) Un procedimiento para preparar mercaptoacilaminoacidos sustituidos con halogeno.
ES8307708A1 (es) Procedimiento para la obtencion de fenoxipropionatos sustituidos.
GR3001195T3 (en) 1,2,3,4,4a,9b-hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
ES8403911A1 (es) Procedimiento de preparacion de mononitratos de 1.4,3.6- dianhidro-hexito sustituidos en 2-0 y 5-0
JPS57171972A (en) Manufacture of quinoline-4-ones
DE3566666D1 (en) Substituted pyridazinones, method for their preparation, pharmaceutical preparation containing these compounds and their use
IE820547L (en) Fluoro-prostacyclins
ES8801805A1 (es) Procedimiento para la obtencion de nuevos derivados de isoxazol
JPS57128674A (en) Growth regulant alpha-azolylglycol, manufacture and plant growth regulant containing same
ES485180A1 (es) Procedimiento para la preparacion de nuevos imidazo (1,2-a) imidazoles
ES8202544A1 (es) Procedimiento para la preparacion de 2-fenilamino-imidazoli-nas -(2) sustituidas
ES8103050A1 (es) Un procedimiento para la preparacion de un derivado de pira-zol

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070317